PATENT CLAIM ANALYSIS

Application Number: 16357918
Application Type: Utility
Filing Date: 2019-03
Publication Date: 2019-09
Patent Classification: ["514", "04400A"]

Abstract:
An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 59.

Claim (Index 13):
A method for restoring an mRNA reading frame to induce dystrophin protein production in a patient with Duchenne muscular dystrophy (DMD) in need thereof who has a mutation of the DMD gene that is amenable to exon 45 skipping, comprising administering to the patient a pharmaceutical composition comprising (i) an antisense oligonucleotide of 22 bases in length, wherein the antisense oligonucleotide is 100% complementary to a target region of exon 45 of the human dystrophin pre-mRNA, wherein the target region is annealing site H45A(\u221203+19), wherein the antisense oligonucleotide is a morpholino antisense oligonucleotide, and wherein the antisense oligonucleotide specifically hybridizes to the annealing site inducing exon 45 skipping, and (ii) a pharmaceutically acceptable carrier, thereby restoring the mRNA reading frame to induce dystrophin protein production in the patient.

Metadata:
- Claim Count in Document: 29.0
- Percentile: 99.0
- Lexical Diversity: 1.10345
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14944886', '14740097', '15661750', '14108137', '13509331']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8035590814741258
- 35 USC 102 Novelty (BERT): 0.785746538238488
- Combined Prediction Score: 0.801777827150562
- Mean Citation Score: 969.5078
- Max Citation Score: 1027.9857
- Similarity Product: 947.0240297837912

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test